Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.
- 1Department of Hematology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye.
- 2Department of Hematology, University of Health Sciences Türkiye, İzmir Tepecik Training and Research Hospital, 35020 İzmir, Türkiye.
Abstract
Background
Anthracycline-containing intensive chemotherapy remains a standard frontline approach for medically fit patients with acute myeloid leukemia (AML). We retrospectively evaluated an exploratory anthracycline-sparing regimen combining fludarabine, cytarabine, and venetoclax (FLA-VEN), with midostaurin added in FLT3-mutated cases, in selected patients with intermediate- or adverse-risk AML.Methods
This retrospective single-center study included 24 consecutive adults with newly diagnosed intermediate- or adverse-risk AML treated between March 2024 and March 2026. Patients with favorable-risk AML were excluded. The primary endpoints were complete remission (CR) and safety. Secondary endpoints included hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rate, relapse incidence, transplant-related mortality (TRM), and overall survival (OS).Results
The median age was 49 years (range, 22-64), and 16.7% of patients were aged ≥60 years. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations were present in 8 patients (33.3%). Following one induction cycle, 21 of 24 patients (87.5%) achieved CR. Among FLT3-ITD-mutated patients, 7 of 8 (87.5%) achieved CR, and FLT3-ITD became undetectable by the available polymerase chain reaction (PCR) fragment assay in all seven responders before transplantation. The 60-day mortality rate was 0/24 (0%). Median neutrophil and platelet recovery times were 17 and 21 days, respectively. Twenty-one patients (87.5%) underwent allo-HSCT in first remission. With a database cutoff of 30 August 2026, Kaplan-Meier estimated OS was 83.3% (95% CI, 61.5-93.4%) at 12 months. The longer-term 24-month OS estimate was 54.4% (95% CI, 25.5-76.3%); however, this estimate was imprecise because only five patients remained at risk at 24 months. Median OS was not reached.Conclusions
In this small exploratory cohort, anthracycline-free and G-CSF-free FLA-VEN, with or without midostaurin, was associated with high remission rates, no early mortality, and frequent bridging to allo-HSCT. These findings support prospective controlled evaluation of this anthracycline-sparing strategy.
Related
- Comparison of patients diagnosed with intimate partner violence with and without brain injury: Retrospective cross-sectional study in a single, urban, academic health system, 2016-2025.
- Case Report: Necrotizing fasciitis caused by Vibrio vulnificus without recalled seafood or seawater exposure diagnosed by metagenomic next-generation sequencing
- Complementary medicine awareness, beliefs, and recent conventional CAM use among university students with and without self-reported previous physician-diagnosed IBS in Palestine
- Incident Atrial Fibrillation Following Anthracycline-Based Adjuvant Chemotherapy in Women with Breast Cancer: A Single-Centre Retrospective Cohort Study.
- Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study
BibTeX
@article{namdaroglu2026anthracyclinefree,
title = {{Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.}},
author = {Sinem Namdaroglu and Merve Kakcı and Berrak Şenol and Osman Can Öztürk and Ömer Şeker and Mehmet Can Uğur and Nanişe Gizem Fener and Semih Başcı and Hikmetullah Batgi},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193132},
url = {https://europepmc.org/article/MED/42882827},
note = {CC BY},
}
RIS
TY - JOUR
TI - Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.
AU - Sinem Namdaroglu
AU - Merve Kakcı
AU - Berrak Şenol
AU - Osman Can Öztürk
AU - Ömer Şeker
AU - Mehmet Can Uğur
AU - Nanişe Gizem Fener
AU - Semih Başcı
AU - Hikmetullah Batgi
PY - 2026
DA - 2026/09/27
JO - Cancers
DO - 10.3390/cancers18193132
UR - https://europepmc.org/article/MED/42882827
AB - Background Anthracycline-containing intensive chemotherapy remains a standard frontline approach for medically fit patients with acute myeloid leukemia (AML). We retrospectively evaluated an exploratory anthracycline-sparing regimen combining fludarabine, cytarabine, and venetoclax (FLA-VEN), with midostaurin added in FLT3-mutated cases, in selected patients with intermediate- or adverse-risk AML.Methods This retrospective single-center study included 24 consecutive adults with newly diagnosed intermediate- or adverse-risk AML treated between March 2024 and March 2026. Patients with favorable-risk AML were excluded. The primary endpoints were complete remission (CR) and safety. Secondary endpoints included hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) rate, relapse incidence, transplant-related mortality (TRM), and overall survival (OS).Results The median age was 49 years (range, 22-64), and 16.7% of patients were aged ≥60 years. FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations were present in 8 patients (33.3%). Following one induction cycle, 21 of 24 patients (87.5%) achieved CR. Among FLT3-ITD-mutated patients, 7 of 8 (87.5%) achieved CR, and FLT3-ITD became undetectable by the available polymerase chain reaction (PCR) fragment assay in all seven responders before transplantation. The 60-day mortality rate was 0/24 (0%). Median neutrophil and platelet recovery times were 17 and 21 days, respectively. Twenty-one patients (87.5%) underwent allo-HSCT in first remission. With a database cutoff of 30 August 2026, Kaplan-Meier estimated OS was 83.3% (95% CI, 61.5-93.4%) at 12 months. The longer-term 24-month OS estimate was 54.4% (95% CI, 25.5-76.3%); however, this estimate was imprecise because only five patients remained at risk at 24 months. Median OS was not reached.Conclusions In this small exploratory cohort, anthracycline-free and G-CSF-free FLA-VEN, with or without midostaurin, was associated with high remission rates, no early mortality, and frequent bridging to allo-HSCT. These findings support prospective controlled evaluation of this anthracycline-sparing strategy.
SN - 2072-6694
ER -